ATG Plus PTCy vs ATG for CGVHD Prophylaxis
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Leukemia
- Chronic Graft Versus Host Disease
- Myelodysplasia
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Randomized pilot trialMasking: None (Open Label)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 16 years and 70 years
- Gender
- Both males and females
Description
Patients with acute leukemia or myelodysplastic syndrome will be randomized to receive, or not receive, post transplant cyclophosphamide in addition to anti-thymocyte globulin.
Patients with acute leukemia or myelodysplastic syndrome will be randomized to receive, or not receive, post transplant cyclophosphamide in addition to anti-thymocyte globulin.
Tracking Information
- NCT #
- NCT04202835
- Collaborators
- Cell Therapy Transplant Canada
- Sanofi
- Ozmosis Research Inc.
- Investigators
- Principal Investigator: Irwin R Walker, MBBS McMaster University Principal Investigator: Kristjan Paulson, MD CancerCare Manitoba
Get Well Soon